We use cookies to improve our website and services. They help us understand how visitors use our website. Some cookies are required for the website to function. These are marked as “essential” in the details.
Cookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
Bavarian Nordic A/S (OMX: BAVA) said it has reached an agreement with CEO Paul Chaplin, who intends to step down for personal reasons. The company stated that Chaplin will remain in the role through the end of 2026, or until a successor has been appointed.
According to Bavarian Nordic, the Board of Directors has started the process of identifying the next CEO.
Nearly three decades with the company
Chaplin joined Bavarian Nordic in 1999 and became CEO in 2014. During his tenure, the company advanced its vaccine for smallpox and mpox, which Bavarian Nordic describes as a meaningful contribution to global public health.
Growth and commercial expansion
Under Chaplin’s leadership, Bavarian Nordic evolved from a research-focused business serving a single government customer into a larger vaccine manufacturer with commercial operations in key markets. The company attributed this development in part to acquisitions in travel vaccines, technology transfer capabilities, and a broader commercial transformation.
Transition planning
Chaplin cited personal circumstances, including his family’s plan to relocate to Australia, and said he will support a stable transition. Board Chair Anne Louise Eberhard thanked Chaplin for his leadership and highlighted both scientific progress and recent commercial performance.
Advertisement
Leading providers in pharma and healthcare marketing
